Journals / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 4

The study of Tau and phospho Tau protein levels in attention deficit and hyperactivity disorder

Pages
2107–2111
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: We concluded that high p-Tau181 might be associated with the progression of ADHD and cognitive changes in ADHD.Key words: Attention deficit and hyperactivity disorder, Tau, phospho Tau

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Attention deficit and hyperactivity disorder (ADHD) is a widespread neurodevelopmental disorder that begins in childhood and has negative consequences throughout adult life.
📊
Key Findings & Data:The excessive phosphorylation of Tau separates the protein from the microtubule, thus making it unstable.
💡
Conclusion & Impact:Conclusion: We concluded that high p-Tau181 might be associated with the progression of ADHD and cognitive changes in ADHD.Key words: Attention deficit and hyperactivity disorder, Tau, phospho Tau
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: Attention deficit and hyperactivity disorder (ADHD) is a widespread neurodevelopmental disorder that begins in childhood and has negative consequences throughout adult life. The etiology and pathogenesis of ADHD are still unclear. Tau protein is a soluble microtubule-related protein expressed by neurons and localized in the cytoplasm as well as axons. Tau protein provides stability of microtubule in two ways: phosphorylation and isoforms. The excessive phosphorylation of Tau separates the protein from the microtubule, thus making it unstable. In this study, we aimed to investigate whether there is a relationship between serum Tau protein and phospho Tau (p-Tau181) levels and ADHD occurrence. Materials and methods: This study included 26 male children aged 7–12 years with newly diagnosed ADHD, who had previously not used any medication for ADHD, and 26 male healthy children. Serum Tau and p-Tau181 concentrations were performed by enzymelinked immunosorbent assay (ELISA). Results: In patients, the Tau levels were not significantly different from those of the controls; the p-Tau181 levels were significantly higher than those of the controls. Conclusion: We concluded that high p-Tau181 might be associated with the progression of ADHD and cognitive changes in ADHD.Key words: Attention deficit and hyperactivity disorder, Tau, phospho Tau

🔖

Cite This Article

DEMİRCİ, E., KILIÇ, E., SARAÇOĞLU, H. (2022). The study of Tau and phospho Tau protein levels in attention deficit and hyperactivity disorder. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 4, 2107–2111. https://ajindex.com/articles/609391

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. American Journal of Psychiatry 2007; 164 (6): 942-948. doi: 10.1176/ajp.2007.164.6.942 2. Willcutt EG. The prevalence of DSM-IV attentiondeficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics 2012; 9 (3): 490-499. doi: 10.1007/s13311- 012-0135-8 3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 6th ed. Washington, DC, USA; 2000
  2. Bray NJ, O’Donovan MC. The genetics of neuropsychiatric disorders. Brain and Neuroscience Advances 2019; 30; 2. doi: 10.1177/2398212818799271 5. Nizynski B, Dzwolak W, Nieznanski K. Amyloidogenesis of Tau protein. Protein Science 2017; 26 (11): 2126-2150. doi: 10.1002/pro.3275 6. Wang Y, Mandelkow E. Tau in physiology and pathology. Nature Reviews Neuroscience 2016; 17 (1): 5-21. doi: 10.1038/ nrn.2015.1 7. Gao YL, Wang N, Sun FR, Cao XP, Zhang W et al. Tau in neurodegenerative disease. Annals of Translational Medicine 2018; 6(10): 175. doi: 10.21037/atm.2018.04.23 8. Spillantini MG, Goedert M. Tau protein pathology in neurodegenerative diseases. Trends in Neuroscience 1998; 21 (10): 428-433. doi: 10.1016/s0166-2236(98)01337-x 9. Demirel ÖF, Cetin I, Turan Ş, Yıldız N, Sağlam T et al. Total Tau and phosphorylated Tau protein serum levels in patients with schizophrenia compared with controls. Psychiatric Quarterly 2017; 88 (4): 921-928. doi: 10.1007/s11126-017-9507-x 10. Lopes S, Vaz-Silva J, Pinto V, Dalla C, Kokras N et al. Tau protein is essential for stress-induced brain pathology. Proceedings of the National Academy of Sciences of the United States of America 2016; 113 (26): E3755-E3763. doi: 10.1073/ pnas.1600953113 11. Dean B, Tsatsanis A, Lam LQ, Scarr E, Duce JA. Changes in cortical protein markers of iron transport with gender, major depressive disorder and suicide. World Journal of Biological Psychiatry 2019; 1-8. doi: 10.1080/15622975.2018.1555377 12. Kadak MT, Cetin I, Tarakçıoğlu MC, Özer ÖF, Kaçar S et al. Low serum level α-synuclein and Tau protein in autism spectrum disorder compared to controls. Neuropediatrics 2015; 46 (6): 410-415. doi: 10.1155/2018/4503871 13. Cetin I, Simsek S. a preliminary study on investigation of serum α-synuclein and Tau protein levels in children with attention deficit hyperactivity disorder. Indian Journal of Clinical Biochemistry 2017; 32 (3): 285-291. doi: 10.1007/ s12291-016-